NYKD.OL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 5245 min ago

@ Kr.14.60

Išleistas: 16 geg. 2024 @ 16:39

Grąža: 0.48%

Ankstesnis signalas: geg. 16 - 13:29

Ankstesnis signalas: Pardavimas

Grąža: -0.48 %

Live Chart Being Loaded With Signals

Commentary (16 geg. 2024 @ 17:25):

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases...

Stats
Šios dienos apimtis	459 602
Vidutinė apimtis	1.00M
Rinkos kapitalizacija	4.79B
EPS	Kr.-0.520 ( 2024-05-16 )
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	-11.28
ATR14	Kr.0.430 (2.93%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: 0.00 (neutral)

Signal:(0) Neutral

Nykode Therapeutics AS Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Nykode Therapeutics AS Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

Financial Reports:

No articles found.

Nykode Therapeutics AS Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.